Home›Companies›Biotech & Pharma›Estrigenix

Estrigenix Therapeutics, Inc.

Develops potential treatments for hot flashes and dementia in postmenopausal women.

Updated Nov 12, 2026·Latest SEC filing Jul 27, 2026·Suggest an edit

About Estrigenix

Estrigenix is a private company based in Wauwatosa, Wisconsin. It has reported $1,000,000 raised in one offering on Form D since July 2026. Its chief executive is Victoria Zellmer.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jul 17, 2026Jul 27, 2026$1,000,000of $2.0M target1$1.0MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Estrigenix's Form D filed Jul 27, 2026.

Patricia Scheller
Patricia Scheller
Executive Chair
Victoria Zellmer
Victoria Zellmer
Chief Executive Officer
William Donaldson
William Donaldson
PRESIDENT & Senior VICE PRESIDENT of CHEMISTRY, director
DS
Daniel Sem
Vice President of Business Development and director
Karyn Frick
Karyn Frick
Chief Scientific Officer

Sources

  1. SECESTRIGENIX THERAPEUTICS, INC. filing history
  2. CompanyAbout Estrigenix